Samaritan's Lead Oral Entry Inhibitor HIV Drug SP01A Initiates PII HIV Monotherapy Trial
Samaritan's Lead Oral Entry Inhibitor HIV Drug SP01A Initiates PII HIV Monotherapy Trial - A Previous Phase II Study plus Multiple Preclinical Studies Suggest SP01A as Preventing HIV From Entering the Human Cell LAS VEGAS, May 11 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative... More...>>

09/16/2004

9:30AM

PRNUS

Samaritan In-Licenses New Alzheimer's Drug From Georgetown University for Further Development
Samaritan In-Licenses New Alzheimer's Drug From Georgetown University for Further Development LAS VEGAS, Sept. 16 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs to target AIDS, Alzheimer's and Cardiovascular disease, announced today, it has been granted an exclusive worldwide... More...>>

LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2009 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs

ADDITIONAL SERVICES AVAILABLE FROM ADVFN
					ADVFN Forex Channel Exchange Rates, FX Prices Charts, Forex Brokers & Currency Conversion

34 site:2us amex liv091125 02:43 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 )